IgG / Life Technologies / ABC / Marneros AG / EPO / Qiagen / Regeneron Pharmaceuticals Inc. / Charles River Laboratories / Pearson / Maldonado AE / Cayman Pharmaceuticals / BD Biosciences / Bio-Rad / Microsoft / /
Currency
pence / USD / / /
Event
FDA Phase / /
Facility
University College London Institute of Ophthalmology / Wilmer Eye Institute / University of Maryland / Johns Hopkins University Pharmacy / The First Affiliated Hospital of Chongqing Medical University / /
IndustryTerm
reagents/analytic tools / serum starvation media / treatment of other diseases / conditioned media / treatment of ocular neovascular disease / therapy for diabetic eye disease / Diabetes Care / treatment of PDR and other ocular neovascular diseases / /
Wilmer Eye Institute / Greenebaum Cancer Center / National Eye Institute / Institutional Review Board / the Johns Hopkins University / Association for Research / University of Maryland / Department of Pathology / Johns Hopkins University Animal Care and Use Committee / Chongqing Medical University / School of Dentistry / Johns Hopkins University / Ella Owens Medical Research Foundation / PDR (red) / University College London Institute of Ophthalmology / Medicare / Institute for Cell Engineering / and Departments of Pediatrics / NS NS / Johns Hopkins University School of Medicine / First Affiliated Hospital / Prevent Blindness Foundation / /
Person
Tao Mab / Sharon Solomona / Savalan Babapoor-Farrokhrana / Monika Deshpandea / Super Signal West Femto (Thermo) / Arch Klin / Akrit Sodhia / Brooks Puchnera / Astrid Limb / Silvia Montanerb / Ella Owens / Kathleen Jeea / George D. Yancopoulos / Syed Junaid Hassana / Gregg L. Semenzad / Adam Wenicka / Arch Ophthalmol / Gerard A. Luttya / / /
PNAS PLUS Angiopoietin-like 4 is a potent angiogenic factor and a novel therapeutic target for patients with proliferative diabetic retinopathy Savalan Babapoor-Farrokhrana,1, Kathleen Jeea,1, Brooks Puchnera, Syed Juna